Theriva 10-Q Reaffirms Going Concern: $8.5M Cash Lasts Only Into Q1 2027
TOVX sits 18% above its 52-week low of $0.136 on light trading volume (0.3× avg).
Summary
Theriva's Q3 10-Q shows a narrower $1.5 million loss and $8.5 million of cash, but management reaffirms substantial doubt about going concern with runway only into Q1 2027 — before the Q3 2027 VIRAGE2 data.
Key Events · Earnings and Guidance · TOVX
-
Q3 Loss Narrows to $1.5 Million
Net loss was $1.5 million, or $0.03 per share, versus $4.4 million, or $0.45 per share, a year earlier; the nine-month loss was $6.7 million versus $21.7 million.
-
Cash Runway Ends Q1 2027
Cash was $8.5 million at September 30, 2026 and $7.5 million in early November, funding operations only into Q1 2027 — before VIRAGE2 data expected in Q3 2027.
-
Going Concern Doubt Reaffirmed
Accumulated deficit reached $365.4 million with working capital of $1.8 million; management cites substantial doubt about continuing as a going concern without new capital or a strategic transaction.
-
New Warrant-Vote Lawsuit Disclosed
Nejmeh v. Theriva Biologics (D. Nev. 3:26-cv-00705) challenges proxy disclosure on the warrant-exercise proposal; a November 18, 2026 special meeting will re-ratify issuance of up to 16,184,560 New Warrant shares and seek authorization of 500,000,000 shares.
Analysis · TOVX · Life Sciences
The Q3 numbers improved — net loss narrowed to $1.5 million from $4.4 million a year earlier, and operating cash burn fell to $8.4 million from $13.8 million — but the balance sheet is the story. Cash stood at $8.5 million on September 30 and $7.5 million in early November, which management says funds operations only into the first quarter of 2027. That is well before the VIRAGE2 Phase 2a data expected in Q3 2027, so the company must raise money or strike a partnership before it can see its own lead readout. The filing also discloses a new Nevada lawsuit over proxy-statement errors on the warrant-exercise vote, and a November 18 special meeting to authorize up to 500 million shares and re-ratify the 16.2 million New Warrant shares — both pointing to further dilution. A $5.0 million deferred Grifols milestone payment would significantly deplete the remaining cash if it comes due.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TOVX was trading at $0.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $0.14 to $0.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.